Screening for Chlamydial Infection: Recommendations and Rationale: U.S. Preventive Services Task Force
United States Preventive Services Task Force
guidelines, medicine, oncology, prevention, screening, skin cancer, u.s. preventive services task force
United States Preventive Services Task Force. Screening for Chlamydial Infection: Recommendations and Rationale: U.S. Preventive Services Task Force. The Internet Journal of Infectious Diseases. 2002 Volume 2 Number 2.
Summary of Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that clinicians routinely screen all sexually active women aged 25 and younger, and other asymptomatic women at increased risk for infection, for chlamydial infection. (see Clinical Considerations for discussion of risk factors). A recommendation.
The USPSTF makes no recommendation for or against routinely screening asymptomatic low-risk women in the general population for chlamydial infection. C recommendation.
The USPSTF recommends that clinicians routinely screen asymptomatic pregnant women aged 25 and younger and others at increased risk for infection for chlamydial infection (see Clinical Considerations for discussion of risk factors in pregnancy). B recommendation.
The USPSTF makes no recommendation for or against routine screening of asymptomatic, low-risk pregnant women aged 26 and older for chlamydial infection. C recommendation.
The USPSTF concludes that the evidence is insufficient to recommend for or against routinely screening asymptomatic men for chlamydial infection. I recommendation.
Women and adolescents through age 20 years are at highest risk for chlamydial infection, but most reported data indicate that infection is prevalent among women aged 20-25.
Age is the most important risk marker. Other patient characteristics associated with a higher prevalence of infection include being unmarried, African-American race, having a prior history of sexually transmitted disease (STD), having new or multiple sexual partners, having cervical ectopy, and using barrier contraceptives inconsistently. Individual risk depends on the number of risk markers and local prevalence of the disease. Specific risk-based screening protocols need to be tested at the local level.
Clinicians should consider the characteristics of the communities they serve in determining appropriate screening strategies for their patient population.
More targeted screening may be indicated in specific settings as better prevalence data become available. Prevalence of chlamydial infection varies widely among communities and patient populations. Knowledge of the patient population is the best guide to developing a screening strategy. Local public health authorities can be a source of valuable information.
The optimal interval for screening is uncertain.
For women with a previous negative screening test, the interval for re-screening should take into account changes in sexual partners. If there is evidence that a woman is at low risk for infection (e.g., in a mutually monogamous relationship with a previous history of negative screening tests for chlamydial infection), it may not be necessary to screen frequently. Re-screening at 6 to 12 months may be appropriate for previously infected women because of high rates of reinfection.
The optimal timing of screening in pregnancy is also uncertain.
Screening early in pregnancy provides greater opportunities to improve pregnancy outcomes, including low birth weight and premature delivery; however, screening in the third trimester may be more effective at preventing transmission of chlamydial infection to the infant during birth. The incremental benefit of repeated screening is unknown.
Screening high-risk young men is a clinical option.
Until the advent of urine-based screening tests, routine screening of men was rarely performed. As a result, very little evidence regarding the efficacy of screening in men in reducing infection among women exists. Trials are underway to assess the effectiveness of screening asymptomatic men. The choice of specific screening technique is left to clinical judgment.
Choice of test will depend on issues of cost, convenience, and feasibility, which may vary in different settings. Although specificity is high with most approved tests, false-positive results can occur with all non-culture tests and rarely with culture tests. The Centers for Disease Control and Prevention (CDC) is developing laboratory guidelines that outline the advantages and disadvantages of available tests. These guidelines will be available at www.cdc.gov in 2001.
Partners of infected individuals should be tested and treated if infected or treated presumptively.
Clinicians should remain alert for findings suggestive of chlamydial infection during pelvic examination of asymptomatic women (e.g., discharge, cervical erythema, and cervical friability).
Clinicians should be sensitive to the potential effect of diagnosing a sexually transmitted disease on a couple.
To prevent false-positive results, confirmatory testing may be appropriate in settings with low population prevalence.
Epidemiology and Clinical Consequences
Seventy percent to 90% of women and a large percentage of men with chlamydial infection are asymptomatic. The prevalence of asymptomatic infection varies widely depending on the population tested and individual characteristics and risk factors, ranging from 4% to 12% among female family planning clinic patients, 9% among female Army recruits, and 2% to 7% among female college students. Significant declines in prevalence have been noted over the last 10 years in areas where screening programs have been in place.
Accuracy and Reliability of Screening Test
A number of tests are available to identify chlamydial infection that use endocervical or urethral swab specimens and urine specimens. Until recently, culture has been accepted as the most specific test but it requires specialized handling and laboratory services. Antigen detection tests (direct fluorescent antibody [DFA] assay and enzyme immunoassay [EIA]) and non-amplified nucleic acid hybridization, as well as newer technologies based on amplified DNA assays (polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement assay (SDA), hybrid capture system (HCS) and transcription-mediated amplification (TMA) of RNA) may provide improved sensitivity, lower expense, availability, or timeliness of results over culture. New tests that use urine specimens provide a noninvasive method of screening both men and women. Self-administered vaginal and vulval-introital swabs using PCR and LCR, including submitting samples by mail, are being used in research settings. The sensitivities and specificities of nucleic acid amplification tests are all high, ranging from 82% to 100%. The sensitivity of antigen detection tests (EIA, DFA) is slightly lower (70%-80%) but specificity remains high (96%-100%).
Effectiveness of Early Detection
The strongest evidence supporting screening is a well-designed randomized trial demonstrating that screening women at risk (prevalence of infection 7%) reduced the incidence of PID from 28 per 1000 woman-years to 13 per 1000 woman-years. The prevalence of chlamydial infection has declined in populations that have been targeted by screening programs (primarily women attending family planning and other publicly funded clinics). In addition, two ecological analyses in Europe reported reductions in ectopic pregnancy and PID with the advent of community-based screening for chlamydial infection. There is little evidence of the effectiveness of screening asymptomatic women who are not in high-risk groups.
There is fair evidence indicating that screening for chlamydial infection among asymptomatic high-risk pregnant women and subsequent treatment improves pregnancy outcomes. Two non-randomized trial studies demonstrated improved pregnancy outcomes following treatment of chlamydial infection: less premature rupture of membranes, less low birth weight, higher infant survival, and fewer small-for-gestational age births. There is little evidence regarding the effectiveness of screening and treatment of asymptomatic pregnant women who are not in high-risk groups.
There is good evidence showing that treatment of men can eradicate chlamydial infection. Unfortunately, there are no studies describing the effectiveness of screening or early treatment of men in reducing acute infection and sequelae in men or women.
Potential Adverse Effects of Screening
No studies were identified that directly examined adverse effects of screening. Potential harms include adverse effects of both false-positive and true-positive diagnoses of STD on patients and their partners, the inconvenience of pelvic examinations for tests employing cervical specimens, and the potential harms of adverse reactions from antibiotic treatment. There may be added cost for confirmation of positive results and testing of partners.
Practice and Policy Considerations
Evaluation of cost-effectiveness of a specific screening strategy considers test performance, cost, treatment and disease outcomes, prevalence of infection in the screened population, and other factors. The USPSTF identified eight cost-effectiveness or cost-benefit analyses that examined screening in nonpregnant and pregnant women. These analyses suggest that screening may be cost-saving when conducted among nonpregnant women who are at moderate to high risk of chlamydial infection. These studies also suggest that selective screening is more likely to be cost-effective than universal screening, and that less expensive and more sensitive DNA or RNA tests would improve cost-effectiveness when compared with culture. However, because of inconsistencies in methodology and assumptions made in these cost analyses, the USPSTF concludes that available evidence on cost-effectiveness is insufficient to guide specific screening recommendations. An interactive model that allows clinicians to compare the cost-effectiveness of different screening strategies is available at http://www.cdc.gov/nchstp/dstd/HEDIS.htm.
Recommendations of Others
The Canadian Task Force on Preventive Health Care4 recommends that all members of high-risk groups be screened for chlamydial infection. The CDC5 recommends at least routine annual screening for sexually active women under age 20 and for women aged 20-24 who meet either of the following criteria: inconsistent use of a barrier contraceptive or more than one sexual partner during the last 3 months, women older than age 24 who meet both criteria of inconsistent use of a barrier contraceptive and more than one sexual partner during the last 3 months. The American College of Obstetricians and Gynecologists6 recommends routine screening for chlamydial infection for all sexually active adolescents and other asymptomatic women at high risk for infection. In 2000, annual chlamydia screening of sexually active women between the ages of 15 and 25 years was added to the National Committee for Quality Assurance Health Plan Employer Data and Information Set (HEDIS)7 quality measures.
The introduction of sensitive, easy-to-use tests has increased the primary care physician's ability to incorporate screening for chlamydial infection into the routine care of younger women, and there is now good evidence that screening can produce important clinical benefits. Important gaps remain, however, in the information needed to guide screening in the primary care setting. Both benefits and cost-effectiveness of screening increase with the prevalence of infection, which varies markedly between communities. There is no agreement, however, on the precise prevalence that justifies screening. Clinical strategies to identify women at risk need to balance feasibility and specificity: more detailed risk assessments may yield more specific information but be harder to implement than asking questions about age and marital status. Moreover, better data on the prevalence and incidence of infection in community practice are needed to develop optimal strategies for screening in a general practice.
The advent of urine-based tests allows for routine specimen collection without a pelvic examination, which may increase acceptability to patients and providers. Urine screening has also spurred interest in screening young men. Asymptomatic young men are an important reservoir for infection and are less likely than women to be detected in the course of usual care. Whether targeting men will be an effective and cost-effective strategy for reducing the burden of disease in women will depend on additional factors that have not been adequately studied, including compliance with therapy, referral of female partners, infectivity of asymptomatic men, and rates of reinfection following treatment. Trials are underway to assess the role of screening men as one strategy for controlling chlamydial infection.
U.S. Preventive Services Task Force
Recommendations and Ratings
U.S. Preventive Services Task Force
Strength of Overall Evidence
Agency for Healthcare Research and Quality http://www.ahrq.gov/
Corresponding Author: Alfred O. Berg, MD, MPH, Chair, U.S. Preventive Services Task Force, c/o David Atkins, MD, MPH, Coordinator for Clinical Preventive Services, U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality, Center for Practice and Technology Assessment, 6010 Executive Boulevard, Suite 300, Rockville, MD 20852. (301) 594-4016, fax (301) 594-4027, E-mail: firstname.lastname@example.org.
Members of the U.S. Preventive Services Task Force are: Alfred O. Berg, MD, MPH, Chair, USPSTF (Professor and Chair, Department of Family Medicine, University of Washington, Seattle, WA); Janet D. Allan, PhD, RN, CS, Vice-chair, USPSTF (Dean and Professor, School of Nursing, University of Texas Health Science Center, San Antonio, TX); Paul S. Frame, MD (Tri-County Family Medicine, Cohocton, NY, and Clinical Professor of Family Medicine, University of Rochester, Rochester, NY); Charles J. Homer, MD, MPH (Executive Director, National Initiative for Children's Healthcare Quality, Boston, MA); Tracy A. Lieu, MD, MPH (Associate Professor, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA); Cynthia D. Mulrow, MD, MSc (Professor of Medicine, University of Texas Health Science Center, Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX); C. Tracy Orleans, PhD (Senior Scientist, The Robert Wood Johnson Foundation, Princeton, NJ); Jeffrey F. Peipert, MD, MPH (Director of Research, Women and Infants' Hospital, Providence, RI); Nola J. Pender, PhD, RN (Professor and Associate Dean for Research, School of Nursing, University of Michigan, Ann Arbor, MI); Harold C. Sox, Jr., MD (Professor and Chair, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH); Steven M. Teutsch, MD, MPH (Senior Director, Outcomes Research and Management, Merck & Company, Inc., West Point, PA); Carolyn Westhoff, MD, MSc (Associate Professor of Obstetrics, Gynecology and Public Health, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY); and Steven H. Woolf, MD, MPH (Professor of Family Medicine, Department of Family Practice, Medical College of Virginia, Fairfax, VA).
Address correspondence to: Alfred O. Berg, MD, MPH, c/o David Atkins, MD, MPH, U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality, Center for Practice and Technology Assessment, 6010 Executive Boulevard, Suite 300, Rockville, MD 20852. E-Mail: email@example.com
Reprints are available from the AHRQ Web site at http://www.ahrq.gov/clinic/uspstfix.htm, through the National Guideline Clearinghouse (http://www.guideline.gov), or in print through the AHRQ Publications Clearinghouse